30 patents
Utility
Methods of Treating Retinal Vasculopathies
20 Oct 22
The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others.
Sharon Klier, Jamie Dananberg
Filed: 12 Apr 22
Utility
Treatment of Parkinson's Disease and Other Conditions Caused or Mediated by Senescent Astrocytes Using Small Molecule Senolytic Agents
31 Mar 22
This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology.
Shankar J. Chinta, Judith Campisi, Julie K. Andersen, Remi-Martin Laberge, Nathaniel David
Filed: 10 Dec 21
Utility
Methods of Inhibiting Pathological Angiogenesis
10 Mar 22
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
Filed: 25 Aug 21
Utility
Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
20 Jan 22
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 3 Jun 21
Utility
Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor
9 Dec 21
This invention is based on the discovery that inhibiting more than one pathway in senescent cells leading to apoptosis has a profound effect: namely, increasing the potency or the cell specificity of the therapy.
Pieter Bas Kwak, Scott Armstrong, Pedro Beltran, Anne-Marie Beausoleil
Filed: 24 Oct 19
Utility
Treating Cardiovascular Disease by Selectively Eliminating Senescent Cells
10 Jun 21
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Jan M.A. van Deursen, Darren J. Baker, Bennett G. Childs
Filed: 7 Dec 20
Utility
Treating Liver Disease by Selectively Eliminating Senescent Cells
10 Jun 21
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia, Yi Zhu
Filed: 7 Dec 20
Utility
Antibodies Directed to TIE-2 and Methods of Use
27 May 21
The invention relates to anti-Tie2 antibodies and methods of using the same.
Jason Damiano, Kristina Oresic Bender, Richard Theolis, Deepika Bhatnagar, Nina Ly
Filed: 19 Nov 20
Utility
Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
11 Mar 21
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 2 Jul 20
Utility
Treating Cognitive Decline and Other Neurodegenerative Conditions by Selectively Removing Senescent Cells from Neurological Tissue
4 Feb 21
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, Jan M.A. van Deursen, Albert Davalos
Filed: 8 Oct 20
Utility
Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
23 Dec 20
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 1 Jul 20
Utility
Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
16 Dec 20
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 20
Utility
Composition Comprising a Gene Vector That Selectively Depletes P16 Positive Senescent Cells
25 Nov 20
Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells.
Serge Lichtsteiner, Nathaniel David
Filed: 19 Dec 19
Utility
Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions
18 Nov 20
Senescent cell medicine encompasses the paradigm that many conditions that are associated with aging or tissue damage are caused or mediated by senescent cells.
Ryan Hudson, Anne-Marie Beausoleil, Remi-Martin Laberge
Filed: 27 Dec 18
Utility
CorrectedTreatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
11 Nov 20
This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Nick Vlahakis, Scott Armstrong, Jamie Dananberg, Ryan Hudson, Anne-Marie Beausoleil, Nathaniel David, Remi-Martin Laberge
Filed: 12 Aug 18
Utility
Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
28 Oct 20
A library of heterocyclic compounds has been screened to identify particular compounds that have high inhibitory capacity for the Bcl family of regulatory proteins.
Nathaniel David, Remi-Martin Laberge
Filed: 3 Jun 20
Utility
Use of a Heterocyclic BCL-2 Inhibitor for Removing Senescent Cells and Treating Senescence-associated Conditions
28 Oct 20
Disclosed herein are compounds that are effective for treatment of various disease states.
Nathaniel David, Remi-Martin Laberge
Filed: 10 Jun 20
Utility
Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
7 Oct 20
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 9 Jun 20
Utility
Acylsulfonamide Derivatives for Treating Senescence-associated Diseases and Disorders
16 Sep 20
Bradley Backes, Thomas W. von Geldern, Bing Chen
Filed: 15 Dec 16
Utility
Methods of Inhibiting Pathological Angiogenesis
12 Aug 20
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
Filed: 13 Feb 20